<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 07 Feb 2021 13:49:08 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>靶点药讯47|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/-fFljRAZEVhYULDb8Zec7g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3FvJSPuuj0JAfbcCfBT3fgQLCnvKQceKHNQUDVFnMjqCIdjdibObxLoQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>科兴中维、阿斯利康、拜耳、基石药业、甘李药业......]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:12:33 +0800</pubDate></item><item><title>信达，再鼎之后，岸迈生物LAG-3/PD-1双抗EMB-02获批临床</title><link>https://mp.weixin.qq.com/s/wh45UUwgf5BKeS24mISQlA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbaHgAOvLBWLia1Tbs7CbF1aNjBwJISFhNiapFBkD8gLknHgxllq6Ak4zicgsIl3ia4zHfGlhQhc3ovmQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:12:33 +0800</pubDate></item><item><title>又一项目被砍，赛诺菲终止venglustat帕金森症II期临床试验</title><link>https://mp.weixin.qq.com/s/s1gcZTUKnErN8bJvivoQDw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbaHgAOvLBWLia1Tbs7CbF1atEK3wXFhbWWb85G24eurpQTkdUJIF02y8aiahewVy85fIq9OP8LK4yQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>新兴生物技术的成熟与落地将逐渐把药企的瘦身变成常态]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:12:33 +0800</pubDate></item><item><title>喜讯！科兴中维新冠灭活疫苗在中国获批上市</title><link>https://mp.weixin.qq.com/s/AppJeK34k1PTrPdX-6xFWg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbaHgAOvLBWLia1Tbs7CbF1a07byFAnqmwjsuaBvPY9ib4IvwdlD9Z5VaXertDzcQpo2BWujPx9nYKw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:12:33 +0800</pubDate></item><item><title>阿斯利康durvalumab在头颈癌中未达标，中国死亡率达52%</title><link>https://mp.weixin.qq.com/s/I4KYlY5Ugh1e6oZ3nTvLjA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZAVFCQ7FyjMC7UnaFiaPCagORmL6Mbv8Ov1TzPwTzsU5VS1QM4rEKY9tdt2S0o7UfWYbjNM1g45mA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>免疫治疗在未来一段时间内仍会是热点。]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>原FDA专家谈国内法规修订原则及中美双报发展趋势</title><link>https://mp.weixin.qq.com/s/P6dYebMWW3eYZB28qp7GLw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZAVFCQ7FyjMC7UnaFiaPCagznOkzeIcbofiaybVGFiacKuRY5uJdia9m7kibbH6NVTEsrOXSzuz9CvWkw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>首发！]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>跌跌撞撞终入局--百时美施贵宝CD19-CAR-T疗法获FDA批准上市</title><link>https://mp.weixin.qq.com/s/v2n7Wa0ciNBal9Bc3iCXdg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZAVFCQ7FyjMC7UnaFiaPCagEHKVYxBjEwOdg83ia1sV3BkiaIibAx9zEsA2ib9wu4Cv5FX9bN2M5EYJew/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>守得云开见月明]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>好消息不断，诺诚健华BTK抑制剂奥布替尼，泛FGFR抑制剂ICP-192均取得临床进展</title><link>https://mp.weixin.qq.com/s/nU0Yrg-bCXy71_e1WC7mjg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZAVFCQ7FyjMC7UnaFiaPCaglp23pJw8kFYToTnyXjl6SsbQEBgqczbqNrAHMdicfbjrUZVibJ1bnyKg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>“土耳其91.25%，巴西50.65%” 科兴公布新冠灭活疫苗III期临床初步分析</title><link>https://mp.weixin.qq.com/s/OEluxRPSDkxbL-F1K0m4ig</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZAVFCQ7FyjMC7UnaFiaPCagU7sCylNP1RgYmUnVJMWDFgfBAeWibV3xwNYtx90icljUibcVlWfozBQAA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>为人类消除疾病提供疫苗]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>最新进展！TG-Bio第二届免疫治疗技术大会4月申城亮相！</title><link>https://mp.weixin.qq.com/s/TD7AvqotZ_So1CPmdPJrFA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZAVFCQ7FyjMC7UnaFiaPCag1QZQos4DVZVhxGyaz7sE3EAQOCjACGpFa68rF2hJ5iaA6meib8Zxq23Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>把握免疫治疗新风向！开春钜献，超值优惠最后一波！]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>罗氏终止若干个2020年临床试验失败的中晚期项目</title><link>https://mp.weixin.qq.com/s/-6Me9d_ctQMWmvEQ5Io8wg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3PF163mhQM9hxOwHksFRQu5NzNZGMWoMh3l0hLy9NicCE6tZTkV1YodQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>罗氏(Roche)正在做一些内部清理工作，以结束第四季度的业绩。]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>恒瑞JAK抑制剂治疗溃疡性结肠炎全球II期临床达到主要终点</title><link>https://mp.weixin.qq.com/s/Zq49VhV6lXyhZ02VKJF7lw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3UqS5QEJdrw1IZN5OSqHBVe8gpbqn9m7jhUXyQxpFrI9O9GeBibGFkOw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>瞄准患者真正的需求，才能让创新有更多的可能。]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>如何提升国内药品质量管理，实现国际并轨？FDA、NMPA如是说</title><link>https://mp.weixin.qq.com/s/sbVHoOi5glyez-9xFcF8zA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3uQlibwFoAm050OjFBmFQw0DP8cSTUhl75bdaoLcozJMiasKpEd0dBzIA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>首发！]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>海和药物提交科创板上市申请，拟募资31.5亿元</title><link>https://mp.weixin.qq.com/s/0oe3ehgSDZoGA702yJHm0A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoN4g4cp4UkheTEuKdLpH8GGbkib8rTlDW1mZLLIPicvicpzv69Rgq5hAiaTA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>套用第五套上市标准]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>安进2020财报：总收入254亿美元！5款药物研发亮红灯</title><link>https://mp.weixin.qq.com/s/4267A7wOrtfsRvwhyCqoGw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNSNJCcBkk7Yaia1AAm3XiaVmav0vJVVzuKrzgHqAVVhGiblJvQAjW81kZQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>生物仿制药的威胁仍然存在]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>GSK加倍下注mRNA技术，1.8亿美元寻找下一代COVID-19疫苗</title><link>https://mp.weixin.qq.com/s/f30jeq0ZNMRiFxbSkVlGig</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNLXqZxoFcXDsM4VBcaoed5poo95eeQSrhTkyHxGEnATxhljhXqsAytA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>“无人问津”到“门庭若市”]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>多地上市成药企潮流，贝达药业港股上市申请获证监会受理</title><link>https://mp.weixin.qq.com/s/iiSdBWg11klpHn-dTFgVfg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNLS14xdjTs46S5Y029R1hJ63WINgZLhmJT01dFRfDicicDKSeuWhEMHUg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷快讯]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>科兴新冠灭活疫苗附条件上市申请获国家药监局受理</title><link>https://mp.weixin.qq.com/s/BhuHJTB9MQy-7vO29miFMQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNiaaxXZ5J4kOqVxiaopfibK6Fj4JUicQGBm22ISvW4WVmB9DRfQhZIINtoQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷分享]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>股价被腰斩，Immunovant公司宣布终止抗FcRn抗体临床研究</title><link>https://mp.weixin.qq.com/s/eVRCiFICMklNHaMn3-axQQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8f3iafSvOstEOKAqcf9r47NVWI0EbatiatBNI1s7IVfxlrGbl86nGIk2tQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>抗FcRn 抗体：自身免疫性疾病的革命性疗法]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>信达生物PD-1单抗在华获批NSCLC领域适应症</title><link>https://mp.weixin.qq.com/s/jTTMbmpgneqtpKJuanvpmg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8fwVvMBLePtpooCIYKgX6OVh6kibrcKibqQjkSiauic19jBdc8dTzQ62UKBw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>今日（2021年2月2日），国家药品监督管理局（NMPA）药品批准证明文件通知显示，信达生物的信迪利单抗注射]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item></channel></rss>